Wenqi Sun, Bei Zhao, Yunrong Wang, Xinrong Wu, Yifan Li, Weiwei Wang, Muhan Ni, Peng Yan, Xiaotan Dou, Wen Li, Hua Yang, Lei Wang, Min Chen
Department of Gastroenterology, the Affiliated Drum Tower Hospital of Nanjing University, Medical School, Nanjing City, P.R. China.
Clin Transl Gastroenterol. 2024 Jan 1;15(1):e00652. doi: 10.14309/ctg.0000000000000652.
Colonoscopy is currently considered as one of the principal techniques to diagnose the colorectal diseases. Admittedly, qualified bowel preparation before colonoscopy is a premise for high-quality examination. Lower quality bowel preparation might seriously impede visualization of the intestinal mucosa, resulting in missed and misdiagnosed intestinal lesions. Therefore, it is necessary to choose the appropriate oral laxative based on the guarantee of safety and efficacy.
This prospective randomized controlled study was conducted to compare lactulose oral solution and polyethylene glycol (PEG) electrolyte powder for bowel preparation using the following indicators: Boston Bowel Preparation Scale, Bowel Bubble Score, detection rate of adenoma and lesion, patients' satisfaction, and adverse effects. Our study investigated the suitability of 2 bowel preparation reagents for patients with different body mass indices mainly based on body mass index (BMI).
In the lactulose group, there was a significant improvement in the quality of bowel preparation compared with those in the PEG group ( P < 0.05), especially in people with normal BMI and higher BMI. Compared with the PEG group, individuals in the lactulose group had a significantly higher adenoma detection rate (50% vs 33.5%, P < 0.05) and taste scores (8.82 vs 6.69, P < 0.05), as well as significantly fewer adverse reactions (6.5% vs 32.5%, P < 0.05).
Lactulose oral solution is superior to PEG in bowel preparation quality and taste, especially in normal BMI and higher BMI groups. It can be used clinically as a potential and promising bowel preparation agent in the future. Clinical Trial registration number: ChiCTR2100054318.
结肠镜检查目前被认为是诊断结直肠疾病的主要技术之一。诚然,结肠镜检查前进行合格的肠道准备是高质量检查的前提。肠道准备质量较低可能会严重妨碍肠黏膜的可视化,导致肠道病变漏诊和误诊。因此,有必要在保证安全性和有效性的基础上选择合适的口服泻药。
本前瞻性随机对照研究旨在比较乳果糖口服溶液和聚乙二醇(PEG)电解质散在肠道准备方面的效果,指标包括:波士顿肠道准备量表、肠气泡评分、腺瘤和病变检出率、患者满意度及不良反应。本研究主要根据体重指数(BMI)调查两种肠道准备试剂对不同BMI患者的适用性。
与PEG组相比,乳果糖组的肠道准备质量有显著改善(P<0.05),尤其是在BMI正常和较高的人群中。与PEG组相比,乳果糖组患者的腺瘤检出率显著更高(50%对33.5%,P<0.05)、口感评分更高(8.82对6.69,P<0.05),且不良反应显著更少(6.5%对32.5%,P<0.05)。
乳果糖口服溶液在肠道准备质量和口感方面优于PEG,尤其是在BMI正常和较高的组中。它未来可作为一种有潜力且有前景的肠道准备剂应用于临床。临床试验注册号:ChiCTR2100054318。